Urology
Volume 74, Issue 4 , Pages 746-749 , October 2009

The Effect of Gastric Banding on Kidney Stone Disease

  • Michelle J. Semins

      Affiliations

    • Department of Urology, The Johns Hopkins University School of Medicine, Baltimore, Maryland
    • ,
  • Brian R. Matlaga

      Affiliations

    • Department of Urology, The Johns Hopkins University School of Medicine, Baltimore, Maryland
    • Corresponding Author InformationReprint requests: Brian R. Matlaga, M.D., M.P.H., James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, 600 North Wolfe St, Baltimore, MD 21287
    • ,
  • Andrew D. Shore

      Affiliations

    • Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland
    • ,
  • Kimberley Steele

      Affiliations

    • Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland
    • ,
  • Thomas Magnuson

      Affiliations

    • Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland
    • ,
  • Roger Johns

      Affiliations

    • Department of Anesthesiology, The Johns Hopkins University School of Medicine, and the Department of Health Policy and Management, Johns Hopkins School of Public Health, Baltimore, Maryland
    • ,
  • Martin A. Makary

      Affiliations

    • Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland

Received 3 February 2009 ,Accepted 22 April 2009.

References 

  1. Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999-2004. J Am Med Assoc. 2006;295:1549–1555
  2. Mydlo JH. The impact of obesity in urology. Urol Clin North Am. 2004;31:275–287
  3. Hinojosa MW, Varela JE, Parikh D, et al. National trends in use and outcome of laparoscopic adjustable gastric banding. Surg Obes Relat Dis. 2009;5:150–155
  4. Santry HP, Gillen DL, Lauderdale DS. Trends in bariatric surgical procedures. J Am Med Assoc. 2005;294:1909–1917
  5. Duffey BG, Pedro RN, Makhlouf A, et al. Roux-en-Y gastric bypass is associated with early increased risk factors for development of calcium oxalate nephrolithiasis. J Am Coll Surg. 2008;206:1145–1153
  6. Asplin JR, Coe FL. Hyperoxaluria in kidney stone formers treated with modern bariatric surgery. J Urol. 2007;177:565–569
  7. Durrani O, Morrisroe S, Jackman S, et al. Analysis of stone disease in morbidly obese patients undergoing gastric bypass surgery. J Endourol. 2006;20:749–752
  8. Sinha MK, Collazo-Clavell ML, Rule A, et al. Hyperoxaluric nephrolithiasis is a complication of roux-en-Y gastric bypass surgery. Kidney Int. 2007;72:100–107
  9. Lieske JC, Kumar R, Collazo-Clavell ML. Nephrolithiasis after bariatric surgery for obesity. Semin Nephrol. 2008;28:163–173
  10. Nelson WK, Houghton SG, Milliner DS, et al. Enteric hyperoxaluria, nephrolithiasis, and oxalate nephropathy: potentially serious and unappreciated complications of roux-en-Y gastric bypass. Surg Obes Relat Dis. 2005;1:481–485
  11. Mole DR, Tomson CR, Mortensen N, et al. Renal complications of jejunoileal bypass for obesity. QJM. 2001;94:69–77
  12. Weiner R, Blanco-Engert R, Weiner S, et al. Outcome after laparoscopic adjustable gastric banding - 8 years experience. Obes Surg. 2003;13:427–434
  13. Pontiroli AE, Pizzocri P, Librenti MC, et al. Laparoscopic adjustable gastric banding for the treatment of morbid (grade 3) obesity and its metabolic complications: a three-year study. J Clin Endocrinol Metab. 2002;87:3555–3561
  14. Nadler EP, Youn HA, Ren CJ, et al. An update on 73 US obese pediatric patients treated with laparoscopic adjustable gastric banding: comorbidity resolution and compliance data. J Pediatr Surg. 2008;43:141–146

 This study was funded by the Hariri Family Foundation and Mr and Mrs Chad and Nissa Richinson. This publication was made possible by Grant Number T32DK07552 from NIH-NIDDK.

 The dataset used in this current study was originally created for a different research project on patterns of obesity care within selected Blue Cross/Blue Shield (BCBS) plans. The previous research project (but not the current study) was funded by unrestricted research grants from Ethicon Endo-Surgery, Inc. (a Johnson & Johnson company); Pfizer, Inc.; and GlaxoSmithKline. The contents of the study are solely the responsibility of the authors and do not necessarily represent the official views of the NIH-NIDDK.

PII: S0090-4295(09)00795-X

doi: 10.1016/j.urology.2009.04.093

Urology
Volume 74, Issue 4 , Pages 746-749 , October 2009

Article Tools